The diagnoses of chronic hepatitis B and liver failure were based on previously described criteria.18, 19 Informed consent was obtained before the study. Studies began after 1 week of the same medical treatments (i.e., reduced glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, Alectinib order alprostadil, and human serum albumin) were performed on all patients. This time point was used as a baseline. All patients were

informed about the process of autologous transplantation of MMSCs and volunteered to receive this treatment. A total of 53 patients (group A) accepted the protocol, and transplantations were performed within 3 days after 1 week of the medical treatments mentioned above. In addition, the medical treatments mentioned above were continued throughout the study for all patients. A total of 105 patients

(group B) matched for age, sex, and some biochemical indexes, including alanine aminotransferase (ALT), albumin (ALB), total bilirubin (TBIL), prothrombin time (PT), and Model for End-Stage Liver Disease (MELD), served as controls (Table 1). In addition, the patients in each group were divided into subgroups of patients with or without cirrhosis: 39 and 77 patients with cirrhosis in subgroups A1 and B1 and 14 and 28 without cirrhosis in subgroups A2 and B2 (no significantly differences were found). Cirrhosis was diagnosed by the evidence of a small, nodular liver, as shown by ultrasound, computerized tomography (CT), and http://www.selleckchem.com/products/mi-503.html magnetic resonance (MR), with the exclusion of primary biliary cirrhosis and cirrhosis caused by schistosome. Inclusion criteria consisted of 15-75 years of age, agreement to informed consent, and a diagnosis of hepatitis B–induced liver failure.18, 19 Exclusion criteria included pregnant

and lactating women, antiviral or immunomodulatory therapy within 6 months before surgery, presence of other factors causing active liver diseases (e.g., autoimmune 上海皓元医药股份有限公司 diseases, drug-induced liver disease, alcoholic liver disease, inherited metabolic liver diseases, etc.), concomitant human immunodeficiency virus (HIV) infection or congenital immune deficiency diseases, proven liver cancer or other malignancies, severe diabetes, autoimmune diseases, other important organ dysfunctions (e.g., kidney dysfunction), concomitant infection (e.g., fever, leukocytosis or neutrophilia, and manifestations of abdominal, biliary tract, or lung infection) or other serous complications (e.g., hepatic encephalopathy, gastrointestinal bleeding, etc.), intolerance to the medical treatments mentioned above, and patients having received, or who would receive, bioartificial liver support therapy or liver transplantation. Our study is registered at ClinicalTrials.gov (NCT00956891), with the registered name of “Long-Term Follow-up of Liver Failure Patients Who Received Autologous Mesenchymal Stem Cells (MSCs) Transplantation.